An In‐Depth Evaluation of CD15 Expression in Thyroid Carcinoma: A Comprehensive Systematic Review
Cancer Reports · 2026-03 · 9 (3)
DOI: 10.1002/cnr2.70519 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Reports, online erschienen am 13.03.2026. Verfasst von Amir Ebrahimzadeh Pasha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Biomarkers, Tumor, Sialyl Lewis X Antigen, Adenocarcinoma, Follicular. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cluster of differentiation 15 (CD15) is a carbohydrate epitope implicated in cell adhesion, migration, and tumor progression. It is variably expressed in thyroid carcinoma (TC) subtypes. However, its diagnostic and prognostic value remains uncertain due to methodological heterogeneity and inconsistent findings.
Aim
To systematically review the prevalence, clinicopathologic associations, and diagnostic utility of CD15 expression across TC subtypes. Methods and Results Following PRISMA guidelines, a systematic search was conducted in May 2025 across PubMed, Scopus, and Web of Science. Sixteen observational studies evaluating CD15 expression in human TC were included. Risk of bias was assessed using the ROBINS‐I tool. A total of 1665 TC cases were analyzed. Classic papillary thyroid carcinoma (CPTC) showed moderate overall prevalence (0%–100%), follicular variant papillary thyroid carcinoma (FVPTC) demonstrated lower expression (17.6%–80%), while tall‐cell papillary thyroid carcinoma (TCPTC) exhibited the highest positivity (71%–100%). Follicular thyroid carcinoma (FTC) showed modest expression, whereas medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) demonstrated overall low positivity. CD15 showed high specificity (90%–100%) for PTC, but sensitivity was inconsistent, particularly in follicular variants.
Conclusion
CD15 demonstrates high specificity for PTC. However, its limited sensitivity and variable expression in follicular‐patterned lesions make its prognostic value unclear. CD15 should not be used as a standalone marker; instead, it may improve diagnostic accuracy when combined with other markers in multiparametric immunohistochemical panels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Faculty of Medicine, Shahed University, Tehran, Iran.
ORCID-Profile: Amir Ebrahimzadeh Pasha, Amirhossein Ehsani, Sara Ashtari, Mohammad Sadeq Najafi, Bardia Baik, Mohammad Mahdi Mehrabi
Zitieren
APA
Ebrahimzadeh Pasha, A., Ehsani, A., Ashtari, S., Najafi, M. S., Baik, B., & Mehrabi, M. M. (2026). An In‐Depth Evaluation of CD15 Expression in Thyroid Carcinoma: A Comprehensive Systematic Review. Cancer Reports, 9(3). https://doi.org/10.1002/cnr2.70519
Vancouver
Ebrahimzadeh Pasha A, Ehsani A, Ashtari S, Najafi MS, Baik B, Mehrabi MM. An In‐Depth Evaluation of CD15 Expression in Thyroid Carcinoma: A Comprehensive Systematic Review. Cancer Reports. 2026;9(3). doi:10.1002/cnr2.70519
BibTeX
@article{EbrahimzadehPasha2026,
author = {Ebrahimzadeh Pasha, Amir and Ehsani, Amirhossein and Ashtari, Sara and Najafi, Mohammad Sadeq and Baik, Bardia and Mehrabi, Mohammad Mahdi},
title = {An In‐Depth Evaluation of CD15 Expression in Thyroid Carcinoma: A Comprehensive Systematic Review},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/cnr2.70519}
}
EUVIMED